-
July 1, 2023 iProgen and Korean Basic Science Institute (KBSI) launches ADC research collaboration to treat Osteoporosis using Antibody Drug Conjugate technologyKorean Basic Science Institute (KBSI) and iProgen Biotech Inc. enters research collaboration to explore the application of Antibody...
-
April 13, 2022 Pioneering research collaboration to treat Sarcopenia using Antibody Drug Conjugate technologyAsan Medical Center (AMC) and iProgen Biotech Inc., enters research collaboration to explore the application of Antibody Drug...
-
April 1, 2022 iProgen and UBC launches ADC research collaboration to develop novel antibody-PROTAC technologyNational Science and Engineering Research Council approves grant to support two-year novel antibody-PROTAC technology research and development. UBC...
-
November 1, 2021 iProgen and Biorchestra launches research collaboration to explore applications of Antibody Oligo Conjugates to treat diseases with unmet medical needsBiorchestra and iProgen have been approved for an International Research Grant application (Canada-Korea) to work on the research...
-
January 20, 2021 Blog standard postLorem ipsum is simply dummy text of the printing and typesetting industry. lorem ipsum has been the industry's...
-
October 28, 2020 East-West academic-industry research collaboration to identify lung cancer biomarkersRIKEN Research Institute, KEIO Medical University, iPrime Therapeutics Co. Ltd., and iProgen Biotech enters joint research collaboration to...
-
April 7, 2019 Celltrion Partners with iProgen Biotech to develop a series of novel ADCsCelltrion signs a partnership deal with the Canada-based iProgen Biotech Inc. to bolster its pipeline for novel biotherapeutics....
Menu
